Better Health for All

Sanofi's core business focuses on pharmaceuticals and vaccines, targeting various diseases including cardiovascular, diabetes, infectious, and cancers.

The company has 35 R&D projects, 15 for priority diseases, and 63 products, with 35 on the WHO Essential Medicines List. Sanofi's collaboration with WHO contributed to reducing sleeping sickness cases from 33,000 in 2000 to fewer than 1,000 in 2019. However, a January 2025 FDA Warning Letter cited significant deviations from Current Good Manufacturing Practice (CGMP) at a Sanofi subsidiary, including approximately 20% of bioreactor runs rejected for contamination or quality failures between January 2022 and July 2024, and 84 open and past-due deviation investigations as of June 2024. Additionally, a Class 2 recall for the Diamigo iPhone App was initiated in 2012 due to inadvertent global access. Sanofi offers reduced prices for essential medicines through its Global Health Unit (GHU) in 10 low- and middle-income countries (LMICs) and has a US patient assistance program for those with household incomes up to 400% of the Federal Poverty Level. The GHU aims to increase access to 30 products in 40 countries, including 35 Least Developed Countries (LDCs). Sanofi publicly reports on access plans and disaggregated R&D investment data, but payment information to healthcare professionals is only disclosed if legally required. The company invested €6.7 billion in R&D in 2023 and plans to increase this by €700 million per year over the next two years. Sanofi's GHU collaborates with local health authorities to train healthcare professionals and raise disease awareness. It has signed strategic training collaborations with the International Diabetes Federation to build healthcare practitioner capacity in 40 LMICs. Sanofi has a preventative medicine, nirsevimab (Beyfortus®), for RSV prevention registered in two countries. During a global health crisis, Sanofi's Foundation S donated 600,000 kits of enoxaparin (Clexane®) to Sri Lanka in 2023. The company acknowledges that neglected tropical diseases (NTDs) can impact mental health due to stigmatization. Sanofi publicly supports the Doha Declaration on TRIPS and Public Health but expresses reservations on compulsory licensing.

Fair Pay & Worker Respect

Sanofi's CEO to median employee pay ratio was 166 to 1 in 2024.

For pay equity, Sanofi UK reported a median gender pay gap of 7.3% in 2024, while Sanofi Ireland reported a median gender pay gap of 6.3% in 2024. In its Irish operations, 263 out of 1,018 employees (approximately 25.8%) were on temporary contracts in 2024. All employees in Sanofi's Irish operations are eligible for fully funded medical benefits, though some opt out.

Fair Trade & Ethical Sourcing

Sustainability assessments for suppliers are renewed at least every three years.

Corrective action plans for suppliers with below-average sustainability scores must be implemented within one year. The Supplier Code of Conduct is incorporated into electronic ordering systems, referenced in the global procurement policy, and suppliers must acknowledge and agree to comply during onboarding. An internal compound rating identifies 47 procurement subcategories as high-risk. Sanofi aims to spend over €1.5 billion with small and diverse businesses by 2025 and to double woman-owned business expenditure by 2025.

Honest & Fair Business

Sanofi was attributed a $458 million penalty in an Attorney General Action in Hawaii related to anti-competitive practices as of June 30, 2024.

The company received a 100% score on Bioethics International Inc.'s Good Pharma Scorecard for transparency, based on a 2017 study. Sanofi operates a 24/7 Speak Up Helpline in 28 languages, run by an independent third-party vendor, and has a zero-tolerance non-retaliation policy for employees, contractors, business partners, suppliers, and value chain workers. The Sanofi Ombuds Office was launched in 2024. In 2024, 900 alerts were raised through the Speak Up Helpline, with 396 cases substantiated, leading to 141 dismissals or resignations. All reporters are notified of receipt within seven days. The target for ethics complaint investigation completion is 90 days, and 90% of medical information inquiries are resolved on the same day. The board of directors has 78% independent directors. Sanofi has a comprehensive Anti-Corruption Program with preventive, detection, and remediation measures, prohibits facilitating payments, and conducts risk-based anti-bribery due diligence on business partners. The company's sustainability information has been subject to certification by statutory auditors in accordance with CSRD requirements, and the Audit Committee oversees sustainability reporting. However, the extent of independent verification of ethical claims is not fully specified beyond this.

Kind to Animals

Sanofi has achieved a 48% reduction in animal use between 2020 and 2024, with a target of 50% reduction by 2030.

The company used 124,905 animals in-house and 42,503 externally in 2024. Sanofi has implemented various in vitro methods, replacing specific animal tests for vaccine potency, bacterial endotoxin, and antibody generation, and one production site has fully ended in vivo quality control activities. All of Sanofi's animal care and use programs either maintained or renewed their AAALAC International accreditation, with 10 out of 12 sites holding this accreditation. The company's policy adheres to the 3Rs principles, prohibits discretionary testing, and requires high-level sign-off for exceptions. Sanofi evaluates external partners and animal suppliers, with 43 contracted research organizations, 29 academic institutions, and 6 animal suppliers assessed in 2024. One contracted research organization was excluded due to a critical discrepancy. Sanofi collaborates with organizations like Humane Society International and Humane Society of the United States on alternative testing methods and is a member of a public-private consortium to reduce non-human primate use. The company advocates for new assay acceptability with regulators and has signed transparency charters in several countries. Sanofi has replaced the use of horseshoe crab reagent with a recombinant alternative, which contributes to preserving natural resources and biodiversity.

No War, No Weapons

Sanofi, a pharmaceutical company, has no defense or arms-related activities in its core business, resulting in 0% revenue from arms contracts and no defense business for board oversight.

The company's general purchase agreement requires suppliers to comply with all applicable trade regulations, including embargoes, and automated controls prevent breaches. Sanofi's Code of Conduct outlines ethical principles, and its Responsible AI Use framework is integrated into this Code, covering biological, chemical, and landmine systems. The company follows the UN Guiding Principles on Business and Human Rights, though implementation is uneven across divisions. Sanofi is a signatory of the United Nations Global Compact and discloses progress annually, but this is a belated declaration for ATT compliance. The company is required by the French Duty of Vigilance Law of 2017 to conduct due diligence, with materiality assessments updated approximately every two years. Sanofi uses AI in drug discovery, clinical trials, and manufacturing, and publishes non-confidential surveillance use cases with ethics board oversight. The company requires suppliers not to use conflict minerals from the Democratic Republic of Congo or adjoining countries, or any other minerals identified as financing conflict.

Planet-Friendly Business

Sanofi's total Scope 1, 2, and 3 greenhouse gas emissions for 2024 were 4,196,976 tCO₂e.

The company has SBTi-validated targets for a 55% reduction in Scope 1 & 2 emissions and a 30% reduction in Scope 3 emissions by 2030, aligned with a 1.5°C pathway. In 2024, 85% of operational energy consumption was sourced from renewables. The share of capital expenditure aligned with the EU Sustainable Taxonomy was 84% in 2024, 89% in 2023, and 99.8% in 2022. The company conducted 27 Life Cycle Assessments in 2024. In 2023, 88% of waste was reused or recovered, with a target of 90% diversion and 1% landfill by 2025. In 2024, 75% of supplier-related emissions were covered by 205 suppliers, but there is no evidence of suppliers having their own SBTi-aligned targets. Sanofi has a net-zero target year of 2045. The company has fully adopted TCFD recommendations and includes climate scenario analysis (1.5°C, 2.8°C, 4°C pathways; IEA scenarios). The company had zero environmental compliance violations in its India subsidiary in 2024. Sanofi plans to offset residual emissions from 2030 onwards, but no current offset quality rating is provided. The company invests €3 million annually in employee sustainability ideas. All sites near biodiversity-sensitive areas will have specific biodiversity management plans by 2030, with priority sites by end-2025. The company sources priority raw materials from deforestation-free sources.

Respect for Cultures & Communities

Sanofi's Innovate Reconciliation Action Plan (RAP) is formally endorsed by Reconciliation Australia, and the company supports the NACCHO Aboriginal and Torres Strait Islander Pharmacist Scholarship program.

These represent two formal engagements with Indigenous groups. Additionally, 3,120 employees completed a bias training workshop in 2021, which is a general diversity training, not specifically cultural sensitivity training.

Safe & Smart Tech

Sanofi has a Responsible AI Governance Body and conducts risk assessments for AI systems.

The company aims to correct bias in AI models, such as adjusting for age-related morbidity in a Gaucher disease model. Sanofi discloses dataset limitations and identifies AI limitations through real-world testing. A cyberattack was prevented by Sanofi's security tools, and the company has a Personal Data Breach Procedure. Sanofi provides mandatory employee training and awareness programs. The company has a Data Subject Rights Procedure. Sanofi's Global Privacy Framework incorporates privacy-by-design principles. Sanofi has Binding Corporate Rules (BCRs) approved by European Data Protection Authorities and complies with French Data Protection Authority (CNIL) methodologies in clinical trials. The company uses Project Searchlight to assess model generalizability across different patient populations.